EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function

Ryuichi Yamazaki, Junya Matsumoto iD, Satsuki Ito, Kiyotaka Nemoto, Masaki Fukunaga, Naoki Hashimoto iD, Fumitoshi Kodaka iD, Harumasa Takano, Naomi Hasegawa, Yuka Yasuda, Michiko Fujimoto, Hidenaga Yamamori und 3 weitere

Neuropsychopharmacology Reports · 2024

DOI: 10.1002/npr2.12423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Ryuichi Yamazaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan. Hauptthemen laut MEDLINE: Schizophrenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Intramural Research Grants for Neurological and Psychiatric Disorders of NCNP, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Establishing a brain biomarker for schizophrenia is strongly desirable not only to support diagnosis by psychiatrists but also to help track the progressive changes in the brain over the course of the illness. A brain morphological signature of schizophrenia was reported in a recent study and is defined by clusters of brain regions with reduced volume in schizophrenia patients compared to healthy individuals. This signature was proven to be effective at differentiating patients with schizophrenia from healthy individuals, suggesting that it is a good candidate brain biomarker of schizophrenia. However, the longitudinal characteristics of this signature have remained unclear. In this study, we examined whether these changes occurred over time and whether they were associated with clinical outcomes. We found a significant change in the brain morphological signature in schizophrenia patients with more brain volume loss than the natural, age‐related reduction in healthy individuals, suggesting that this change can capture a progressive morphological change in the brain. We further found a significant association between changes in the brain morphological signature and changes in the full‐scale intelligence quotient (IQ). The patients with IQ improvement showed preserved brain morphological signatures, whereas the patients without IQ improvement showed progressive changes in the brain morphological signature, suggesting a link between potential recovery of intellectual abilities and the speed of brain pathology progression. We conclude that the brain morphological signature is a brain biomarker that can be used to evaluate progressive changes in the brain that are associated with cognitive impairment due to schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaHumansIntelligenceSchizophrenic PsychologyCognitionBrainBiomarkers

Stichwörter der Autor:innen

biomarkercognitive declinelongitudinal studyschizophreniastructural MRI

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Developmental and Clinical Psychology, The Division of Human Developmental Sciences, Graduate School of Humanity and Sciences, Ochanomizu University, Tokyo, Japan.
  • Department of Psychiatry, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Section of Brain Function Information, National Institute for Physiological Sciences, Okazaki, Japan.
  • Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

ORCID-Profile: Junya Matsumoto, Naoki Hashimoto, Fumitoshi Kodaka, Kenichiro Miura, Ryota Hashimoto

Förderung

  • Japan Agency for Medical Research and Development
  • Intramural Research Grants for Neurological and Psychiatric Disorders of NCNP
  • Japan Society for the Promotion of Science

Zitieren

APA

Yamazaki, R., Matsumoto, J., Ito, S., Nemoto, K., Fukunaga, M., Hashimoto, N., Kodaka, F., Takano, H., Hasegawa, N., Yasuda, Y., Fujimoto, M., Yamamori, H., Watanabe, Y., Miura, K., & Hashimoto, R. (2024). Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12423

Vancouver

Yamazaki R, Matsumoto J, Ito S, Nemoto K, Fukunaga M, Hashimoto N, et al. Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12423

BibTeX
@article{Yamazaki2024,
  author = {Yamazaki, Ryuichi and Matsumoto, Junya and Ito, Satsuki and Nemoto, Kiyotaka and Fukunaga, Masaki and Hashimoto, Naoki and Kodaka, Fumitoshi and Takano, Harumasa and Hasegawa, Naomi and Yasuda, Yuka and Fujimoto, Michiko and Yamamori, Hidenaga and Watanabe, Yoshiyuki and Miura, Kenichiro and Hashimoto, Ryota},
  title = {Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function},
  journal = {Neuropsychopharmacology Reports},
  year = {2024},
  doi = {10.1002/npr2.12423}
}
Kostenlos starten →